Literature DB >> 19828073

Conditional independence relations among biological markers may improve clinical decision as in the case of triple negative breast cancers.

Federico M Stefanini1, Danila Coradini, Elia Biganzoli.   

Abstract

The associations existing among different biomarkers are important in clinical settings because they contribute to the characterisation of specific pathways related to the natural history of the disease, genetic and environmental determinants. Despite the availability of binary/linear (or at least monotonic) correlation indices, the full exploitation of molecular information depends on the knowledge of direct/indirect conditional independence (and eventually causal) relationships among biomarkers, and with target variables in the population of interest. In other words, that depends on inferences which are performed on the joint multivariate distribution of markers and target variables. Graphical models, such as Bayesian Networks, are well suited to this purpose. Therefore, we reconsidered a previously published case study on classical biomarkers in breast cancer, namely estrogen receptor (ER), progesterone receptor (PR), a proliferative index (Ki67/MIB-1) and to protein HER2/neu (NEU) and p53, to infer conditional independence relations existing in the joint distribution by inferring (learning) the structure of graphs entailing those relations of independence. We also examined the conditional distribution of a special molecular phenotype, called triple-negative, in which ER, PR and NEU were absent. We confirmed that ER is a key marker and we found that it was able to define subpopulations of patients characterized by different conditional independence relations among biomarkers. We also found a preliminary evidence that, given a triple-negative profile, the distribution of p53 protein is mostly supported in 'zero' and 'high' states providing useful information in selecting patients that could benefit from an adjuvant anthracyclines/alkylating agent-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19828073      PMCID: PMC2762062          DOI: 10.1186/1471-2105-10-S12-S13

Source DB:  PubMed          Journal:  BMC Bioinformatics        ISSN: 1471-2105            Impact factor:   3.169


  14 in total

1.  Flexible modelling in survival analysis. Structuring biological complexity from the information provided by tumor markers.

Authors:  E Biganzoli; P Boracchi; M G Daidone; M Gion; E Marubini
Journal:  Int J Biol Markers       Date:  1998 Jul-Sep       Impact factor: 2.659

2.  Using Bayesian networks to analyze expression data.

Authors:  N Friedman; M Linial; I Nachman; D Pe'er
Journal:  J Comput Biol       Date:  2000       Impact factor: 1.479

3.  Bayesian networks in biomedicine and health-care.

Authors:  Peter J F Lucas; Linda C van der Gaag; Ameen Abu-Hanna
Journal:  Artif Intell Med       Date:  2004-03       Impact factor: 5.326

4.  Prediction of cancer outcome with microarrays.

Authors:  Elia Biganzoli; Nicola Lama; Federico Ambrogi; Laura Antolini; Patrizia Boracchi
Journal:  Lancet       Date:  2005 May 14-20       Impact factor: 79.321

5.  Predicting the prognosis of breast cancer by integrating clinical and microarray data with Bayesian networks.

Authors:  Olivier Gevaert; Frank De Smet; Dirk Timmerman; Yves Moreau; Bart De Moor
Journal:  Bioinformatics       Date:  2006-07-15       Impact factor: 6.937

6.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

Authors:  Sunil R Lakhani; Marc J Van De Vijver; Jocelyne Jacquemier; Thomas J Anderson; Peter P Osin; Lesley McGuffog; Douglas F Easton
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

7.  Understanding tuberculosis epidemiology using structured statistical models.

Authors:  Lise Getoor; Jeanne T Rhee; Daphne Koller; Peter Small
Journal:  Artif Intell Med       Date:  2004-03       Impact factor: 5.326

8.  Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.

Authors:  Lajos Pusztai; Mark Ayers; James Stec; Edward Clark; Kenneth Hess; David Stivers; Andrew Damokosh; Nour Sneige; Thomas A Buchholz; Francisco J Esteva; Banu Arun; Massimo Cristofanilli; Daniel Booser; Marguerite Rosales; Vicente Valero; Constantine Adams; Gabriel N Hortobagyi; W Fraser Symmans
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

9.  Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods.

Authors:  Federico Ambrogi; Elia Biganzoli; Patrizia Querzoli; Stefano Ferretti; Patrizia Boracchi; Saverio Alberti; Ettore Marubini; Italo Nenci
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

10.  Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Authors:  Marc Tischkowitz; Jean-Sébastien Brunet; Louis R Bégin; David G Huntsman; Maggie C U Cheang; Lars A Akslen; Torsten O Nielsen; William D Foulkes
Journal:  BMC Cancer       Date:  2007-07-24       Impact factor: 4.430

View more
  1 in total

1.  Chain graph models to elicit the structure of a Bayesian network.

Authors:  Federico M Stefanini
Journal:  ScientificWorldJournal       Date:  2014-02-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.